Development of broad-spectrum enterovirus antivirals based on quinoline scaffold

Rami Musharrafieh,Naoya Kitamura,Yanmei Hu,Jun Wang
DOI: https://doi.org/10.1016/j.bioorg.2020.103981
IF: 5.307
2020-08-01
Bioorganic Chemistry
Abstract:<p>Non-polio enteroviruses such as enterovirus A71 (EV-A71), EV-D68, and coxsackievirus B3 (CVB3) are significant human pathogens with disease manifestations ranging from mild flu-like symptoms to more severe encephalitis, myocarditis, acute flaccid paralysis/myelitis, and even death. There is currently no effective antivirals to prevent or treat non-polio enterovirus infection. In this study, we report our progress in developing potent and broad-spectrum antivirals against these non-polio enteroviruses. Starting from our previously developed lead compounds that had potent antiviral activity against EV-D68, we synthesized 43 analogs and profiled their broad-spectrum antiviral activity against additional EV-D68, EV-A71, and CVB3 viruses. Promising candidates were also selected for mouse microsomal stability test to prioritize lead compounds for future in vivo mouse model studies. Collectively, this multi-parameter optimization process revealed a promising lead compound <strong>6aw</strong> that showed single-digit to submicromolar EC<sub>50</sub> values against two EV-D68 strains (US/KY and US/MO), two EV-A71 strains (Tainan and US/AK), and one CVB3 strain, with a high selectivity index. Encouragingly, <strong>6aw</strong> was stable in mouse microsomes with a half-life of 114.7 min. Overall, <strong>6aw</strong> represents one of the most potent broad-spectrum antiviral against non-polio enteroviruses, rendering it a promising lead candidate for non-polio enteroviruses with translational potential.</p>
biochemistry & molecular biology,chemistry, organic
What problem does this paper attempt to address?